CA2498180C - Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses - Google Patents
Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses Download PDFInfo
- Publication number
- CA2498180C CA2498180C CA2498180A CA2498180A CA2498180C CA 2498180 C CA2498180 C CA 2498180C CA 2498180 A CA2498180 A CA 2498180A CA 2498180 A CA2498180 A CA 2498180A CA 2498180 C CA2498180 C CA 2498180C
- Authority
- CA
- Canada
- Prior art keywords
- poly
- carbon dioxide
- polymeric material
- densified carbon
- dioxide composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
Abstract
Methods of producing biocompatible intraluminal prostheses are provided and include immersing polymeric material of an intraluminal prosthesis in a densified carbon dioxide composition under controlled conditions such that toxic materials are absorbed by the densified carbon dioxide composition.
Description
CARBON DIOXIDE-ASSISTED METHODS OF PROVIDING
BIOCOMPATIBLE INTRALUMINAL PROSTHESES
FIELD OF THE INVENTION
The present invention relates generally to medical devices and, more particularly, to methods of providing biocompatible medical devices.
BACKGROUND OF THE INVENTION
Stents are typically used as adjuncts to is percutaneous transluminal balloon angioplasty procedures, in the treatment of occluded or partially occluded arteries and other blood vessels. As an example of a balloon angioplasty procedure, a guiding catheter or sheath is percutaneously introduced into the cardiovascular system of a patient through the femoral arteries and advanced through the vasculature until the distal end of the guiding catheter is positioned at a point proximal to the lesion site. A guidewire and a dilatation catheter having a balloon on the distal end are introduced through the guiding catheter with the guidewire sliding within the dilatation catheter. The guidewire is first advanced out of the guiding catheter into the patient's vasculature and is directed across the arterial lesion. The dilatation catheter is subsequently advanced over the previously advanced guidewire until the dilatation balloon is properly positioned across the arterial lesion. once in position across the lesion, the expandable balloon-is,inflated to a predetermined size with a radiopaque liquid at relatively high pressure to radially compress the atherosclerotic plaque of the lesion against the inside of the artery wall and.thereby dilate the lumen of the artery. The balloon is then deflated to a small profile so that the dilatation catheter can be withdrawn from the patient's vasculature and blood flow resumed through the dilated artery.
Balloon angioplasty sometimes results in short or long term failure (restenosis). That is, vessels may abruptly close shortly after the procedure or restenosis may occur gradually over a period of months thereafter.
To counter restenosis following angioplasty, implantable intraluminal prostheses,, commonly referred to as stents, are used to achieve long term vessel patency. A stent functions as scaffolding to structurally support the vessel wall and thereby maintain luminal patency, and are transported to a lesion site by means of a delivery catheter.
Types of stents may include balloon expandable stents, spring-like, self-expandable stents, and thermally expandable stents. Balloon expandable stents are delivered by a dilitation catheter and are plastically deformed by an expandable member, such as an inflation balloon, from a small initial diameter to a larger expanded diameter. Self-expanding stents are formed as spring elements which are radially compressible about a delivery catheter. A compressed self-expanding stent is typically held in the compressed state by a delivery sheath. Upon del4veryy to a lesion site, the delivery sheath is retracted allowing the stent to expand. Thermally expandable stents are formed from shape memory alloys which have the ability to expand from a small initial diameter to a second larger diameter upon the application of heat to the alloy.
Polymeric materials are increasingly being utilized in intraluminal prostheses, such as stents, as well as in other types of medical devices used within the bodies of subjects. Polymeric materials conventionally utilized in the medical device industry for implantation within the bodies of subjects include, but are not limited to polyurethanes, polyolefins (e.g., polyethylene and polypropylene), poly(meth)acrylates, polyesters (e.g., polyethyleneterephthalate), polyamides, polyvinyl resins, silicon resins (e.g., silicone rubbers and polysiloxanes), polycarbonates, polyfluorocarbon resins, synthetic resins, and polystyrene.
Many conventional polymeric materials contain a range of additives (e.g., plasticizers, antioxidants, W
stabilizers, etc.) as well as a host of contaminants (e.g., residual monomer, oligomers, solvent residues, catalysts, initiators, etc.). For example, casting solvents such as dimethyl sulfoxide (DMSO), chloro-organics, aromatics, tetrahydrofuran (THF), etc. are conventionally utilized in stent production. Moreover, various toxic organic solvents and plasticizers are conventionally used to impregnate the polymeric material of implantable devices, such as intraluminal prostheses, with pharmacological agents. Trace quantities of these materials may remain in the polymeric materials during fabrication of these devices and patients receiving these devices, or pharmacological agents eluted therefrom, may be exposed to these potentially toxic materials, particularly when the implantable device erodes.
As such, it is desirable to purify polymeric materials utilized in medical devices, such as intraluminal prostheses, in order to remove solvents and other potentially toxic materials and to enhance the biocompatibility of the polymeric material.
Unfortunately, conventional purification methods may involve applying heat to the polymeric material. The addition of heat may alter the physical characteristics of the polymeric material, thus negatively affecting the biocompatibility of the material.
SUMMARY OF THE INVENTION
Methods of producing biocompatible intraluminal prostheses according to embodiments of the present invention utilize densified carbon dioxide to remove toxic materials. According to embodiments of the present invention, the polymeric material of an intraluminal prosthesis is immersed in a densified carbon dioxide composition to absorb toxic materials (e.g., organic solvents (polar or non-polar), unpolymerized monomers, polymerization catalysts, and polymerization initiators, etc..) therefrom. The term "toxic materials" includes all types of foreign materials, contaminants, chemicals,.
physical impurities, and the like, without limitation, that may be harmful to a subject. The densified carbon dioxide composition containing the toxic materials is then removed (completely or partially) from the polymeric material and the toxic materials are easily be separated from the carbon dioxide composition by decreasing the density of the carbon dioxide.
According to an aspect of the present invention, there is provided a method of producing a stent comprising:
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern: temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition; and removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use.
According to another aspect of the present invention, there is provided a method of producing a stent comprising:
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern: temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition, wherein pressure and/or - 4a -temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;
removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use;
lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and removing the separated toxic materials.
- 4b -BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a flowchart of operations for impregnating polymeric material with pharmacological agents, according to embodiments of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention now is described more fully hereinafter with reference to the accompanying drawings, in which embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The term "biocompatible" as used herein, is intended to denote a material that upon contact with a living element such as a cell or tissue, does not cause toxicity.
The term "dosage regimen" is used herein to describe both exogenously administered and internally administered pharmacological agents. A dosage regimen includes both an amount of a pharmacological agent and time(s) that each dose is to be taken. A dosage regimen may also indicate whether a pharmacological agent is to be taken with food or not, and whether other pharmacological agents are to be avoided.
The term "eluting" is used herein to mean the release of a pharmacological agent from a polymeric material. Eluting may also refer to the release of a material from a substrate via diffusional mechanisms or by release from a polymeric material/substrate as a result of the breakdown, or erosion of the material/substrate.
The term "erodible" as used herein refers to the ability of a material to maintain its structural integrity for a desired period of time, and thereafter gradually undergo any of numerous processes whereby the material substantially loses tensile strength and mass.
Examples of such processes comprise enzymatic and non-enzymatic hydrolysis, oxidation, enzymatically-assisted oxidation, and others, thus including bioresorption, dissolution, and mechanical degradation upon interaction with a physiological environment into components that the patient's tissue can absorb, inetabolize, respire, and/or excrete. The terms "erodible"'and "degradable" are intended to be used herein interchangeably.
The term "hydrophobic" is used herein to mean not soluble in water.
The term "hydrophilic" is used herein to mean soluble in water.
The term "lumen" is used herein to mean any inner open space or cavity of a body passageway.
The terms "polymer" and "polymeric material"
are synonymous and are to be broadly construed to include, but not be limited to, homopolymers, copolymers, terpolymers, and the like.
The term "prosthesis" is used herein in a broad sense to denote any type of intraluminal prosthesis or other device which is implanted in the body of a subject for some therapeutic reason or purpose including, but not limited to stents, drug delivery devices, etc.
The term "subject" is used herein to describe both human beings and animals (e.g., mammalian subjects) for medical, veterinary, testing and/or screening purposes.
The term "toxic materials" is intended to include all types of foreign materials, contaminants, chemicals, physical impurities, and the like, without limitation, that may be harmful to a subject.
As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted to include X and Y.
As used herein, phrases such as "between about X and Y" mean "between about X and about Y."
As used herein, phrases such as "from about X
to Y" mean "from about X to about Y."
Referring now to Fig. 1, methods of producing biocompatible intraluminal prostheses (e.g., stents, etc.), according to embodiments of the present invention are illustrated. Embodiments of the present invention can be employed in conjunction with a number of manufacturing processes associated with producing intraluminal prostheses including, but not limited to, extrusion, pultrusion, injection molding, etc. Moreover, embodiments of the present invention may be utilized in batch, semicontinuous, or continuous processes.
An intraluminal prosthesis (e.g., a stent, drug delivery device, etc.) comprising polymeric material (e.g., formed from polymeric material, or having a partial or complete coating of polymeric material) is provided (Block 100). The polymeric material may contain trace amounts of one or more toxic materials as a result of previous fabrication steps. For example, residual amounts of various casting solvents including, but not limited to, organic solvents (polar or non-polar) such as DMSO, dimethyl acetimide (DMAc), dimethyl foramide (DMF), chloro-organics, aromatics (such as benzene, toluene, xylene, chlorobenzene), THF, TFF, diglyac glycol, esters, etc. may be present, as would be understood by one skilled in the art. In addition, unpolymerized monomers, oligomers, polymerization initiators, catalysts, etc. may be present, as would be understood by one skilled in the art. Oligomers are undesired, low molecular weight molecules that may be linear or cyclic.
According to embodiments of the present invention, levels of toxic materials can be reduced to predetermined, acceptable values in parts per million (ppm) based upon specific toxic materials. For example, toxic material "A" that is present in the polymeric material of an intraluminal prosthesis at levels of from greater than 200, 400, 600, 800 or 1,000 ppm, may be reduced to "acceptable" values of, for example, 20, 50, 100, 200, or 400 ppm, etc.
Exemplary polymeric materials that may be utilized in intraluminal prostheses (and in accordance with embodiments of the present invention) include, but are not limited to, polyurethanes, polyolefins, poly(meth)acrylates, polyesters, polyamides, polyvinyl resins, silicon resins, polycarbonates, polyfluorocarbon resins, synthetic resins, and polystyrene. In addition, polymeric material of intraluminal prostheses may be erodible (or an intraluminal prosthesis may have an erodible coating) or non-erodible (or an intraluminal prosthesis may have a non-erodible coating).
Intraluminal prostheses according to embodiments of the present invention, may be formed from various materials. In addition, intraluminal prostheses having polymeric coatings, according to embodiments of the present invention, may be metallic prostheses or polymeric prostheses.
Exemplary erodible materials that may be utilized in intraluminal prostheses (and in accordance with embodiments of the present invention) include, but are not limited to, surgical gut, silk, cotton, liposomes, poly(hydroxybutyrate), polycarbonates, polyacrylates, polyanhydrides, polyethylene glycol, poly(ortho esters), poly(phosphoesters), polyesters, polyamides (such as polyamides derived from D-glucose), polyphosphazenes, poly(p-dioxane), poly(amino acid), polyglactin, and copolymers thereof, erodible hydrogels, natural polymers such as collagen and chitosan, etc. See, e.g.,-U.S. Patent No. 5,723,508 to Healy et al.
Particular examples of suitable erodible polymers include, but are not limited to, aliphatic polyester polymers such as poly(lactic acid), poly(L-lactic acid), poly(D,L-lactic acid), poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), poly (D,L-lactic-co-glycolic acid), poly(E-caprolactone), poly(valerolactone), poly(hydroxy butyrate) (including poly(hydroxy butyrate valerate)), poly(hydrovalerate), polydioxanone, poly(propylene fumarate), etc., including copolymers thereof such as polylactic acid-polyethylene glycol block copolymer, and poly (ethyleneoxide)-poly(butylenetetraphthalate), poly(lactic acid-co-lysine), poly(E-caprolactone copolymers), poly (L-lactic acid copolymers), etc. See, e.g., J. Oh et al., PCT Application W0*99/59548 at page
BIOCOMPATIBLE INTRALUMINAL PROSTHESES
FIELD OF THE INVENTION
The present invention relates generally to medical devices and, more particularly, to methods of providing biocompatible medical devices.
BACKGROUND OF THE INVENTION
Stents are typically used as adjuncts to is percutaneous transluminal balloon angioplasty procedures, in the treatment of occluded or partially occluded arteries and other blood vessels. As an example of a balloon angioplasty procedure, a guiding catheter or sheath is percutaneously introduced into the cardiovascular system of a patient through the femoral arteries and advanced through the vasculature until the distal end of the guiding catheter is positioned at a point proximal to the lesion site. A guidewire and a dilatation catheter having a balloon on the distal end are introduced through the guiding catheter with the guidewire sliding within the dilatation catheter. The guidewire is first advanced out of the guiding catheter into the patient's vasculature and is directed across the arterial lesion. The dilatation catheter is subsequently advanced over the previously advanced guidewire until the dilatation balloon is properly positioned across the arterial lesion. once in position across the lesion, the expandable balloon-is,inflated to a predetermined size with a radiopaque liquid at relatively high pressure to radially compress the atherosclerotic plaque of the lesion against the inside of the artery wall and.thereby dilate the lumen of the artery. The balloon is then deflated to a small profile so that the dilatation catheter can be withdrawn from the patient's vasculature and blood flow resumed through the dilated artery.
Balloon angioplasty sometimes results in short or long term failure (restenosis). That is, vessels may abruptly close shortly after the procedure or restenosis may occur gradually over a period of months thereafter.
To counter restenosis following angioplasty, implantable intraluminal prostheses,, commonly referred to as stents, are used to achieve long term vessel patency. A stent functions as scaffolding to structurally support the vessel wall and thereby maintain luminal patency, and are transported to a lesion site by means of a delivery catheter.
Types of stents may include balloon expandable stents, spring-like, self-expandable stents, and thermally expandable stents. Balloon expandable stents are delivered by a dilitation catheter and are plastically deformed by an expandable member, such as an inflation balloon, from a small initial diameter to a larger expanded diameter. Self-expanding stents are formed as spring elements which are radially compressible about a delivery catheter. A compressed self-expanding stent is typically held in the compressed state by a delivery sheath. Upon del4veryy to a lesion site, the delivery sheath is retracted allowing the stent to expand. Thermally expandable stents are formed from shape memory alloys which have the ability to expand from a small initial diameter to a second larger diameter upon the application of heat to the alloy.
Polymeric materials are increasingly being utilized in intraluminal prostheses, such as stents, as well as in other types of medical devices used within the bodies of subjects. Polymeric materials conventionally utilized in the medical device industry for implantation within the bodies of subjects include, but are not limited to polyurethanes, polyolefins (e.g., polyethylene and polypropylene), poly(meth)acrylates, polyesters (e.g., polyethyleneterephthalate), polyamides, polyvinyl resins, silicon resins (e.g., silicone rubbers and polysiloxanes), polycarbonates, polyfluorocarbon resins, synthetic resins, and polystyrene.
Many conventional polymeric materials contain a range of additives (e.g., plasticizers, antioxidants, W
stabilizers, etc.) as well as a host of contaminants (e.g., residual monomer, oligomers, solvent residues, catalysts, initiators, etc.). For example, casting solvents such as dimethyl sulfoxide (DMSO), chloro-organics, aromatics, tetrahydrofuran (THF), etc. are conventionally utilized in stent production. Moreover, various toxic organic solvents and plasticizers are conventionally used to impregnate the polymeric material of implantable devices, such as intraluminal prostheses, with pharmacological agents. Trace quantities of these materials may remain in the polymeric materials during fabrication of these devices and patients receiving these devices, or pharmacological agents eluted therefrom, may be exposed to these potentially toxic materials, particularly when the implantable device erodes.
As such, it is desirable to purify polymeric materials utilized in medical devices, such as intraluminal prostheses, in order to remove solvents and other potentially toxic materials and to enhance the biocompatibility of the polymeric material.
Unfortunately, conventional purification methods may involve applying heat to the polymeric material. The addition of heat may alter the physical characteristics of the polymeric material, thus negatively affecting the biocompatibility of the material.
SUMMARY OF THE INVENTION
Methods of producing biocompatible intraluminal prostheses according to embodiments of the present invention utilize densified carbon dioxide to remove toxic materials. According to embodiments of the present invention, the polymeric material of an intraluminal prosthesis is immersed in a densified carbon dioxide composition to absorb toxic materials (e.g., organic solvents (polar or non-polar), unpolymerized monomers, polymerization catalysts, and polymerization initiators, etc..) therefrom. The term "toxic materials" includes all types of foreign materials, contaminants, chemicals,.
physical impurities, and the like, without limitation, that may be harmful to a subject. The densified carbon dioxide composition containing the toxic materials is then removed (completely or partially) from the polymeric material and the toxic materials are easily be separated from the carbon dioxide composition by decreasing the density of the carbon dioxide.
According to an aspect of the present invention, there is provided a method of producing a stent comprising:
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern: temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition; and removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use.
According to another aspect of the present invention, there is provided a method of producing a stent comprising:
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern: temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition, wherein pressure and/or - 4a -temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;
removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use;
lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and removing the separated toxic materials.
- 4b -BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a flowchart of operations for impregnating polymeric material with pharmacological agents, according to embodiments of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention now is described more fully hereinafter with reference to the accompanying drawings, in which embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The term "biocompatible" as used herein, is intended to denote a material that upon contact with a living element such as a cell or tissue, does not cause toxicity.
The term "dosage regimen" is used herein to describe both exogenously administered and internally administered pharmacological agents. A dosage regimen includes both an amount of a pharmacological agent and time(s) that each dose is to be taken. A dosage regimen may also indicate whether a pharmacological agent is to be taken with food or not, and whether other pharmacological agents are to be avoided.
The term "eluting" is used herein to mean the release of a pharmacological agent from a polymeric material. Eluting may also refer to the release of a material from a substrate via diffusional mechanisms or by release from a polymeric material/substrate as a result of the breakdown, or erosion of the material/substrate.
The term "erodible" as used herein refers to the ability of a material to maintain its structural integrity for a desired period of time, and thereafter gradually undergo any of numerous processes whereby the material substantially loses tensile strength and mass.
Examples of such processes comprise enzymatic and non-enzymatic hydrolysis, oxidation, enzymatically-assisted oxidation, and others, thus including bioresorption, dissolution, and mechanical degradation upon interaction with a physiological environment into components that the patient's tissue can absorb, inetabolize, respire, and/or excrete. The terms "erodible"'and "degradable" are intended to be used herein interchangeably.
The term "hydrophobic" is used herein to mean not soluble in water.
The term "hydrophilic" is used herein to mean soluble in water.
The term "lumen" is used herein to mean any inner open space or cavity of a body passageway.
The terms "polymer" and "polymeric material"
are synonymous and are to be broadly construed to include, but not be limited to, homopolymers, copolymers, terpolymers, and the like.
The term "prosthesis" is used herein in a broad sense to denote any type of intraluminal prosthesis or other device which is implanted in the body of a subject for some therapeutic reason or purpose including, but not limited to stents, drug delivery devices, etc.
The term "subject" is used herein to describe both human beings and animals (e.g., mammalian subjects) for medical, veterinary, testing and/or screening purposes.
The term "toxic materials" is intended to include all types of foreign materials, contaminants, chemicals, physical impurities, and the like, without limitation, that may be harmful to a subject.
As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted to include X and Y.
As used herein, phrases such as "between about X and Y" mean "between about X and about Y."
As used herein, phrases such as "from about X
to Y" mean "from about X to about Y."
Referring now to Fig. 1, methods of producing biocompatible intraluminal prostheses (e.g., stents, etc.), according to embodiments of the present invention are illustrated. Embodiments of the present invention can be employed in conjunction with a number of manufacturing processes associated with producing intraluminal prostheses including, but not limited to, extrusion, pultrusion, injection molding, etc. Moreover, embodiments of the present invention may be utilized in batch, semicontinuous, or continuous processes.
An intraluminal prosthesis (e.g., a stent, drug delivery device, etc.) comprising polymeric material (e.g., formed from polymeric material, or having a partial or complete coating of polymeric material) is provided (Block 100). The polymeric material may contain trace amounts of one or more toxic materials as a result of previous fabrication steps. For example, residual amounts of various casting solvents including, but not limited to, organic solvents (polar or non-polar) such as DMSO, dimethyl acetimide (DMAc), dimethyl foramide (DMF), chloro-organics, aromatics (such as benzene, toluene, xylene, chlorobenzene), THF, TFF, diglyac glycol, esters, etc. may be present, as would be understood by one skilled in the art. In addition, unpolymerized monomers, oligomers, polymerization initiators, catalysts, etc. may be present, as would be understood by one skilled in the art. Oligomers are undesired, low molecular weight molecules that may be linear or cyclic.
According to embodiments of the present invention, levels of toxic materials can be reduced to predetermined, acceptable values in parts per million (ppm) based upon specific toxic materials. For example, toxic material "A" that is present in the polymeric material of an intraluminal prosthesis at levels of from greater than 200, 400, 600, 800 or 1,000 ppm, may be reduced to "acceptable" values of, for example, 20, 50, 100, 200, or 400 ppm, etc.
Exemplary polymeric materials that may be utilized in intraluminal prostheses (and in accordance with embodiments of the present invention) include, but are not limited to, polyurethanes, polyolefins, poly(meth)acrylates, polyesters, polyamides, polyvinyl resins, silicon resins, polycarbonates, polyfluorocarbon resins, synthetic resins, and polystyrene. In addition, polymeric material of intraluminal prostheses may be erodible (or an intraluminal prosthesis may have an erodible coating) or non-erodible (or an intraluminal prosthesis may have a non-erodible coating).
Intraluminal prostheses according to embodiments of the present invention, may be formed from various materials. In addition, intraluminal prostheses having polymeric coatings, according to embodiments of the present invention, may be metallic prostheses or polymeric prostheses.
Exemplary erodible materials that may be utilized in intraluminal prostheses (and in accordance with embodiments of the present invention) include, but are not limited to, surgical gut, silk, cotton, liposomes, poly(hydroxybutyrate), polycarbonates, polyacrylates, polyanhydrides, polyethylene glycol, poly(ortho esters), poly(phosphoesters), polyesters, polyamides (such as polyamides derived from D-glucose), polyphosphazenes, poly(p-dioxane), poly(amino acid), polyglactin, and copolymers thereof, erodible hydrogels, natural polymers such as collagen and chitosan, etc. See, e.g.,-U.S. Patent No. 5,723,508 to Healy et al.
Particular examples of suitable erodible polymers include, but are not limited to, aliphatic polyester polymers such as poly(lactic acid), poly(L-lactic acid), poly(D,L-lactic acid), poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), poly (D,L-lactic-co-glycolic acid), poly(E-caprolactone), poly(valerolactone), poly(hydroxy butyrate) (including poly(hydroxy butyrate valerate)), poly(hydrovalerate), polydioxanone, poly(propylene fumarate), etc., including copolymers thereof such as polylactic acid-polyethylene glycol block copolymer, and poly (ethyleneoxide)-poly(butylenetetraphthalate), poly(lactic acid-co-lysine), poly(E-caprolactone copolymers), poly (L-lactic acid copolymers), etc. See, e.g., J. Oh et al., PCT Application W0*99/59548 at page
2. Additional examples of erodible polymers are set forth in U.S. Patent No. 5,916,585 to Cook et al. at col. 9 line 53 to col. 10 line 22. The molecular weight (that is, average molecular weight) of the polymer may be from 1,000, 10,000, 100,000 or 500,000 to 2,000,000 or 4,000,000 Daltons, or more. Exemplary non erodible materials that may be utilized in intraluminal prostheses (and in accordance with embodiments of the present invention) include, but are not limited to, fluoropolymers, polyesters, PET, polyethylenes, polypropylenes, etc., and/or ceramics, such as
3 PCT/US2003/033644 hydroxyapetite.
Moreover, intraluminal prostheses may include various pharmacological agents. In general, pharmacological agents suitable for inclusion in prosthesis materials and/or coatings (and according to embodiments of the present invention) include, but are not limited to, drugs and other biologically active materials, and may be intended to perform a variety of functions, including, but not limited to: anti-cancer treatment (e.g., Resan), anti-clotting or anti-platelet formation, the prevention of smooth muscle cell growth, migration, proliferation` within a vessel wall.
Pharmacological agents may include antineoplastics, antimitotics, antiinflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antiproliferatives, antibiotics, antioxidants, and antiallergic substances as well as combinations thereof.
Examples of antineoplastics and/or antimitotics include paclitaxel (cytostatic and ant-inflammatory) and it's analogs and all compounds in the TA.XOL (Bristol-Myers Squibb Co., Stamford, Conn.) family of pharmaceuticals, docetaxel (e.g., TAXOTERE from Aventis S. A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride 25, (e.g., ADRIAMYCIN from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g., MUTAMYCIN from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of antiinflammatories include Sirolimus and it's analogs (including but not limited to Everolimus and all compounds in the Limus family of pharmaceuticals), glucocorticoids such as dexamethasone, methylprednisclone, hydrocortisone and betamethasone and non-steroidal antiinflammatories such as aspirin, indomethacin and ibuprofen. Examples of antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Iib/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as AngiomaxTl" (Biogen, Inc., Cambridge, Mass.) Examples of cytostatic or antiproliferative agents or proliferation inhibitors include everolimus, actinomycin D, as well as derivatives and analogs thereof (manufactured by Sigma-Aldrich, Milwaukee, Wis.; or COSMEGEN available from Merck & Co., Inc., Whitehouse Station, N.J.), angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g., CAPOTEN and CAPOZIDE from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g., Prinivilo and PRINZIDE from Merck & Co., Inc., Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name MEVACOR from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents that may be used include alphainterferon, genetically engineered epithelial cells, and dexamethasone.
U.S. Patent Nos. 4,994,033 to Shockey et al.;
5,674,192 to Sahatian et al. and 5,545,208 to Wolff et al. disclose catheters comprising absorbable/ --biodegradable polymers or hydrogels containing the desired dosage of a drug. Stents incorporating drug delivery may be found, for example, in U.S. Patent Nos.
5,766,710 to Turnlund et al.; 5,769,883 to Buscemi et al.; 5,605,696 to Eury et al.; 5,500,013 to Buscemi et al.; 5,551,954 to Buscemi et al. and 5,443,458 to Eury, Referring back to Fig. 1, the polymeric material of an'intraluminal prosthesis is immersed in a densified (e.g., liquid or supercritical) carbon dioxide composition for a time sufficient, and under controlled conditions, to cause the trace amounts of toxic materials to be absorbed by the densified carbon dioxide composition (Block 110). Carbon dioxide is non-toxic, non-flammable, chemically inert, completely recoverable, abundant and inexpensive. Carbon dioxide has properties that are between those of many liquids and gases. At room temperature and above its vapor pressure, carbon dioxide exists as a liquid with a density comparable to organic solvents but with excellent wetting properties and a very low viscosity. Above its critical temperature and pressure (3C and 73.8 bar), carbon dioxide is in the supercritical state and has gas-like viscosities and liquid-like densities. Small changes in temperature or pressure cause dramatic changes in the density, viscosity, and dielectric properties of supercritical carbon dioxide, making it an unusually tunable, versatile, and selective solvent.
The densified carbon dioxide composition, according to embodiments of the present invention, may be heterogeneous or homogeneous in composition, i.e., may be a single phase composition or contain one or more additional phases, such as in the form of a microemulsion, emulsion, dispersion, suspension, etc.
The densified carbon dioxide composition may comprise, consist of, or consist essentially of carbon dioxide.
Where multiple phases are found in the densified carbon dioxide composition, the carbon dioxide may be in the continuous phase.
One or more other ingredients may be included in the densified carbon dioxide composition, such as co-solvents (i.e.,_water or organic co-solventsFsuch.as .ethanol and methanol), surfactants or the like may be included. Where one or more organic co-solvents are included, it or they'may be polar or nonpolar (or at least one of each). Where one or more surfactants are included it or they may comprise a carbon dioxide-philic group coupled to either a lipophilic or hydrophilic group, a conventional surfactant comprising a liphophilic group coupled to a hydrophilic group, or one or more of each. The densified carbon dioxide composition may comprise at least.30, 40, 50, 60, 70, 80 or 90 percent by weight of carbon dioxide. When water is present in the densified carbon dioxide composition, the water may comprise from about 0.01, 0.1, or 0.5 to about. 1, 5, 10 or 20 percent by weight of the composition, or more.
Immersing the polymeric material of the intraluminal prosthesis in the densified carbon dioxide composition under controlled conditions includes, but is not limited to, controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern: temperature, rate of temperature change, pressure, rate of pressure change, composition quantity, etc. Changes in one or more of these parameters (also referred to as "tuning" the densified carbon dioxide composition) can be made to selectively absorb trace amounts of toxic materials.
Moreover, changes in one or more of these parameters can control both the effectiveness and efficiency of toxic material removal.
Referring back to Fig. 1, the densified carbon dioxide composition containing the toxic materials is removed from contact with the polymeric material (Block 120). Removal may include complete removal or partial removal. The density of the removed densified carbon dioxide composition is lowered such that the trace amounts of toxic materials entrained therein become separated therefrom (Block 130). The separated toxic materials are then disposed of (Block 140). The density of the removed densified carbon dioxide composition may be lowered by reducing pressure and/or increasing temperature, as would be understood by one skilled in the .art.
Embodiments of the present invention described above with respect to Fig. 1 may be carried out using apparatus known to those skilled in the art. Immersing the polymeric material of an intraluminal prosthesis in a densified carbon dioxide composition for a time sufficient (Block 110) may be performed within an - enclosed chamber (e.g., pressure vessel). Lowering the density of the densified carbon dioxide composition (Block 130) may also be performed within an enclosed chamber, for example an enclosed chamber separate from a chamber within which the polymeric material is immersed in the densified carbon dioxide composition.
According to embodiments of the present invention, selective removal of toxic or other materials may be accomplished via any of a variety of known masking techniques. For example, a mask may be applied to one or more portions of an intraluminal prosthesis such that toxic materials are removed only from non-masked portions of the polymeric material . Masking techniques are well understood by those skilled in the art and need not be described further herein.
Intraluminal prostheses provided in accordance with embodiments of the present invention may be employed in sites of the body other than the vasculature including, but not limited to, biliary tree, esophagus, bowels, tracheo-bronchial tree, urinary tract, etc.
The scope of the claims should not be limited by the preferred embodiments set forth above, but should be given the broadest interpretation consistent with the description as a whole.
Moreover, intraluminal prostheses may include various pharmacological agents. In general, pharmacological agents suitable for inclusion in prosthesis materials and/or coatings (and according to embodiments of the present invention) include, but are not limited to, drugs and other biologically active materials, and may be intended to perform a variety of functions, including, but not limited to: anti-cancer treatment (e.g., Resan), anti-clotting or anti-platelet formation, the prevention of smooth muscle cell growth, migration, proliferation` within a vessel wall.
Pharmacological agents may include antineoplastics, antimitotics, antiinflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antiproliferatives, antibiotics, antioxidants, and antiallergic substances as well as combinations thereof.
Examples of antineoplastics and/or antimitotics include paclitaxel (cytostatic and ant-inflammatory) and it's analogs and all compounds in the TA.XOL (Bristol-Myers Squibb Co., Stamford, Conn.) family of pharmaceuticals, docetaxel (e.g., TAXOTERE from Aventis S. A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride 25, (e.g., ADRIAMYCIN from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g., MUTAMYCIN from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of antiinflammatories include Sirolimus and it's analogs (including but not limited to Everolimus and all compounds in the Limus family of pharmaceuticals), glucocorticoids such as dexamethasone, methylprednisclone, hydrocortisone and betamethasone and non-steroidal antiinflammatories such as aspirin, indomethacin and ibuprofen. Examples of antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Iib/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as AngiomaxTl" (Biogen, Inc., Cambridge, Mass.) Examples of cytostatic or antiproliferative agents or proliferation inhibitors include everolimus, actinomycin D, as well as derivatives and analogs thereof (manufactured by Sigma-Aldrich, Milwaukee, Wis.; or COSMEGEN available from Merck & Co., Inc., Whitehouse Station, N.J.), angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g., CAPOTEN and CAPOZIDE from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g., Prinivilo and PRINZIDE from Merck & Co., Inc., Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name MEVACOR from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents that may be used include alphainterferon, genetically engineered epithelial cells, and dexamethasone.
U.S. Patent Nos. 4,994,033 to Shockey et al.;
5,674,192 to Sahatian et al. and 5,545,208 to Wolff et al. disclose catheters comprising absorbable/ --biodegradable polymers or hydrogels containing the desired dosage of a drug. Stents incorporating drug delivery may be found, for example, in U.S. Patent Nos.
5,766,710 to Turnlund et al.; 5,769,883 to Buscemi et al.; 5,605,696 to Eury et al.; 5,500,013 to Buscemi et al.; 5,551,954 to Buscemi et al. and 5,443,458 to Eury, Referring back to Fig. 1, the polymeric material of an'intraluminal prosthesis is immersed in a densified (e.g., liquid or supercritical) carbon dioxide composition for a time sufficient, and under controlled conditions, to cause the trace amounts of toxic materials to be absorbed by the densified carbon dioxide composition (Block 110). Carbon dioxide is non-toxic, non-flammable, chemically inert, completely recoverable, abundant and inexpensive. Carbon dioxide has properties that are between those of many liquids and gases. At room temperature and above its vapor pressure, carbon dioxide exists as a liquid with a density comparable to organic solvents but with excellent wetting properties and a very low viscosity. Above its critical temperature and pressure (3C and 73.8 bar), carbon dioxide is in the supercritical state and has gas-like viscosities and liquid-like densities. Small changes in temperature or pressure cause dramatic changes in the density, viscosity, and dielectric properties of supercritical carbon dioxide, making it an unusually tunable, versatile, and selective solvent.
The densified carbon dioxide composition, according to embodiments of the present invention, may be heterogeneous or homogeneous in composition, i.e., may be a single phase composition or contain one or more additional phases, such as in the form of a microemulsion, emulsion, dispersion, suspension, etc.
The densified carbon dioxide composition may comprise, consist of, or consist essentially of carbon dioxide.
Where multiple phases are found in the densified carbon dioxide composition, the carbon dioxide may be in the continuous phase.
One or more other ingredients may be included in the densified carbon dioxide composition, such as co-solvents (i.e.,_water or organic co-solventsFsuch.as .ethanol and methanol), surfactants or the like may be included. Where one or more organic co-solvents are included, it or they'may be polar or nonpolar (or at least one of each). Where one or more surfactants are included it or they may comprise a carbon dioxide-philic group coupled to either a lipophilic or hydrophilic group, a conventional surfactant comprising a liphophilic group coupled to a hydrophilic group, or one or more of each. The densified carbon dioxide composition may comprise at least.30, 40, 50, 60, 70, 80 or 90 percent by weight of carbon dioxide. When water is present in the densified carbon dioxide composition, the water may comprise from about 0.01, 0.1, or 0.5 to about. 1, 5, 10 or 20 percent by weight of the composition, or more.
Immersing the polymeric material of the intraluminal prosthesis in the densified carbon dioxide composition under controlled conditions includes, but is not limited to, controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern: temperature, rate of temperature change, pressure, rate of pressure change, composition quantity, etc. Changes in one or more of these parameters (also referred to as "tuning" the densified carbon dioxide composition) can be made to selectively absorb trace amounts of toxic materials.
Moreover, changes in one or more of these parameters can control both the effectiveness and efficiency of toxic material removal.
Referring back to Fig. 1, the densified carbon dioxide composition containing the toxic materials is removed from contact with the polymeric material (Block 120). Removal may include complete removal or partial removal. The density of the removed densified carbon dioxide composition is lowered such that the trace amounts of toxic materials entrained therein become separated therefrom (Block 130). The separated toxic materials are then disposed of (Block 140). The density of the removed densified carbon dioxide composition may be lowered by reducing pressure and/or increasing temperature, as would be understood by one skilled in the .art.
Embodiments of the present invention described above with respect to Fig. 1 may be carried out using apparatus known to those skilled in the art. Immersing the polymeric material of an intraluminal prosthesis in a densified carbon dioxide composition for a time sufficient (Block 110) may be performed within an - enclosed chamber (e.g., pressure vessel). Lowering the density of the densified carbon dioxide composition (Block 130) may also be performed within an enclosed chamber, for example an enclosed chamber separate from a chamber within which the polymeric material is immersed in the densified carbon dioxide composition.
According to embodiments of the present invention, selective removal of toxic or other materials may be accomplished via any of a variety of known masking techniques. For example, a mask may be applied to one or more portions of an intraluminal prosthesis such that toxic materials are removed only from non-masked portions of the polymeric material . Masking techniques are well understood by those skilled in the art and need not be described further herein.
Intraluminal prostheses provided in accordance with embodiments of the present invention may be employed in sites of the body other than the vasculature including, but not limited to, biliary tree, esophagus, bowels, tracheo-bronchial tree, urinary tract, etc.
The scope of the claims should not be limited by the preferred embodiments set forth above, but should be given the broadest interpretation consistent with the description as a whole.
Claims (26)
1. A method of producing a stent comprising:
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern:
temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition; and removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use.
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern:
temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition; and removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use.
2. The method of claim 1, wherein the one or more toxic materials are selected from the group consisting of organic solvents, unpolymerized monomers, polymerization catalysts, oligomers, and polymerization initiators.
3. The method of claim 2, wherein the organic solvents are polar or non-polar.
4. The method of claim 1, wherein the densified carbon dioxide composition is a liquid composition, and wherein the immersing and removing steps are carried out in an enclosed chamber.
5. The method of claim 1, wherein the immersing step comprises adjusting the pressure and/or temperature of the densified carbon dioxide composition to selectively absorb toxic materials from the polymeric material.
6. The method of claim 1, further comprising:
lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and removing the separated toxic materials.
lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and removing the separated toxic materials.
7. The method of claim 6, wherein the step of lowering the density comprises reducing pressure and/or increasing temperature of the densified carbon dioxide composition.
8. The method of claim 1, wherein carbon dioxide in the densified carbon dioxide composition is present in a supercritical state.
9. The method of claim 1, wherein the carbon dioxide contains one or more of a co-solvent, a surfactant, and a co-surfactant.
10. The method of claim 1, further comprising masking one or more portions of the polymeric material prior to immersing the polymeric material in the densified carbon dioxide composition.
11. The method of claim 1, wherein the polymeric material is erodible.
12. The method of claim 1, wherein the polymeric material is non-erodible.
13. The method of claim 1, wherein the polymeric material is a coating on one or more portions of the stent.
14. The method of claim 11, wherein the erodible polymeric material is selected from the group consisting of, surgical gut, silk, cotton, liposomes, poly(hydroxybutyrate), polycarbonate, polyacrylate, polyanhydride, polyethylene glycol, poly(ortho esters), poly(phosphoesters), polyesters, polyamides, polyphosphazenes, poly(p-dioxane), poly(amino acid), polyglactin, erodible hydrogels, collagen, chitosan, poly(lactic acid), poly(L-lactic acid), poly(D,L-lactic acid), poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), poly(D,L-lactic-co-glycolic acid), poly (c-caprolactone), poly(valerolactone), poly (hydroxy butyrate), poly(hydrovalerate), polydioxanone, poly(propylene fumarate), poly(ethyleneoxide)-poly(butylenetetraphthalate), poly(lactic acid-co-lysine), poly(L-lactic acid) and poly(.epsilon.-caprolactone) copolymers.
15. A method of producing a stent comprising:
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern:
temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition, wherein pressure and/or temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;
removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use;
lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and removing the separated toxic materials.
providing a stent having a portion thereof formed from polymeric material, wherein the polymeric material contains one or more toxic materials;
immersing the polymeric material in a densified carbon dioxide composition and controlling one or more of the following parameters associated with the densified carbon dioxide composition in a predetermined pattern:
temperature, rate of temperature change, pressure, rate of pressure change, and composition quantity, to absorb the toxic materials by the densified carbon dioxide composition, wherein pressure and/or temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;
removing the densified carbon dioxide composition containing the toxic materials from the polymeric material, such that the stent is suitable for in vivo use;
lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and removing the separated toxic materials.
16. The method of claim 15, wherein the one or more toxic materials are selected from the group consisting of organic solvents, unpolymerized monomers, polymerization catalysts, oligomers, and polymerization initiators.
17. The method of claim 16, wherein the organic solvents are polar or non-polar.
18. The method of Claim 16, wherein the densified carbon dioxide composition is a liquid composition, and wherein the immersing and removing steps are carried out in an enclosed chamber.
19. The method of claim 16, wherein the step of lowering the density comprises reducing pressure and/or increasing temperature of the densified carbon dioxide composition.
20. The method of claim 16, wherein carbon dioxide in the densified carbon dioxide composition is present in a supercritical state.
21. The method of claim 16, further comprising masking one or more portions of the polymeric material prior to immersing the polymeric material in the densified carbon dioxide composition.
22. The method of claim 16, wherein the polymeric material is erodible.
23. The method of claim 16, wherein the polymeric material is non-erodible.
24. The method of claim 16, wherein the carbon dioxide contains one or more of a co-solvent, a surfactant, and a co-surfactant.
25. The method of claim 16, wherein the polymeric material is a coating on one or more portions of the stent.
26. The method of claim 22, wherein the erodible polymeric material is selected from the group consisting of, surgical gut, silk, cotton, liposomes, poly(hydroxybutyrate), polycarbonate, polyacrylate, polyanhydride, polyethylene glycol, poly(ortho esters), poly(phosphoesters), polyesters, polyamides, polyphosphazenes, poly(p-dioxane), poly(amino acid), polyglactin, erodible hydrogels, collagen, chitosan, poly(lactic acid), poly(L-lactic acid), poly(D,L-lactic acid), poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), poly(D,L-lactic-co-glycolic acid), poly (.epsilon.-caprolactone), poly(valerolactone), poly (hydroxy butyrate), poly(hydrovalerate), polydioxanone, poly(propylene fumarate), poly(ethyleneoxide)-poly(butylenetetraphthalate), poly(lactic acid-co-lysine), poly(L-lactic acid) and poly(.epsilon.-caprolactone) copolymers.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42612602P | 2002-11-14 | 2002-11-14 | |
| US60/426,126 | 2002-11-14 | ||
| US10/662,621 | 2003-09-15 | ||
| US10/662,621 US7285287B2 (en) | 2002-11-14 | 2003-09-15 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
| PCT/US2003/033644 WO2004047873A2 (en) | 2002-11-14 | 2003-10-23 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2498180A1 CA2498180A1 (en) | 2004-06-10 |
| CA2498180C true CA2498180C (en) | 2013-04-16 |
Family
ID=32302669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2498180A Expired - Fee Related CA2498180C (en) | 2002-11-14 | 2003-10-23 | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7285287B2 (en) |
| EP (1) | EP1560489A4 (en) |
| JP (1) | JP4617258B2 (en) |
| AU (1) | AU2003284338B2 (en) |
| CA (1) | CA2498180C (en) |
| WO (1) | WO2004047873A2 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU716005B2 (en) * | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
| US7065779B1 (en) * | 1999-10-13 | 2006-06-20 | Cisco Technology, Inc. | Technique for synchronizing multiple access controllers at the head end of an access network |
| US7660621B2 (en) | 2000-04-07 | 2010-02-09 | Medtronic, Inc. | Medical device introducer |
| US7704260B2 (en) | 2002-09-17 | 2010-04-27 | Medtronic, Inc. | Low profile instrument immobilizer |
| US7580756B2 (en) * | 2004-02-13 | 2009-08-25 | Medtronic, Inc. | Methods and apparatus for securing a therapy delivery device within a burr hole |
| US7635510B2 (en) * | 2004-07-07 | 2009-12-22 | Boston Scientific Scimed, Inc. | High performance balloon catheter/component |
| US20070196423A1 (en) * | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
| US8048448B2 (en) * | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
| WO2008070189A2 (en) | 2006-12-06 | 2008-06-12 | The Cleveland Clinic Foundation | Method and system for treating acute heart failure by neuromodulation |
| ES2407851T3 (en) * | 2008-03-27 | 2013-06-14 | Mitsui Chemicals, Inc. | Resin composition and use thereof |
| US8298466B1 (en) | 2008-06-27 | 2012-10-30 | Abbott Cardiovascular Systems Inc. | Method for fabricating medical devices with porous polymeric structures |
| US8642063B2 (en) * | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
| JP5820370B2 (en) | 2009-05-20 | 2015-11-24 | アーセナル メディカル， インコーポレイテッド | Medical implant |
| US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
| US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
| US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
| US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
| US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
| US8795309B2 (en) * | 2009-07-29 | 2014-08-05 | Smiths Medical Asd, Inc. | Device for insertion of a cannula of an infusion device and method |
| US8372133B2 (en) | 2009-10-05 | 2013-02-12 | 480 Biomedical, Inc. | Polymeric implant delivery system |
| EP2485688B1 (en) * | 2009-10-06 | 2019-09-04 | Sahajanand Medical Technologies Private Limited | Bioresorbable vascular implant having homogenously distributed stresses under a radial load |
| CN111790047B (en) | 2014-05-22 | 2022-09-27 | 卡迪诺米克公司 | Catheter and catheter system for electrical neuromodulation |
| EP3194007B1 (en) | 2014-09-08 | 2018-07-04 | Cardionomic, Inc. | Catheter and electrode systems for electrical neuromodulation |
| AU2015315570B2 (en) | 2014-09-08 | 2020-05-14 | CARDIONOMIC, Inc. | Methods for electrical neuromodulation of the heart |
| EP3610917A1 (en) | 2015-01-05 | 2020-02-19 | Cardionomic, Inc. | Cardiac modulation facilitation methods and systems |
| CA3015372A1 (en) | 2016-03-09 | 2017-09-14 | CARDIONOMIC, Inc. | Cardiac contractility neurostimulation systems and methods |
| US11191930B2 (en) | 2016-04-12 | 2021-12-07 | Boston Scientific Scimed, Inc. | Medical balloon |
| US10849629B2 (en) | 2016-12-13 | 2020-12-01 | Boston Scientific Scimed, Inc. | Medical balloon |
| US10987496B2 (en) | 2017-04-25 | 2021-04-27 | Boston Scientific Scimed, Inc. | Medical balloon |
| WO2019055434A1 (en) | 2017-09-13 | 2019-03-21 | CARDIONOMIC, Inc. | Neurostimulation systems and methods for affecting cardiac contractility |
| SG11202101191PA (en) | 2018-08-13 | 2021-03-30 | Cardionomic Inc | Systems and methods for affecting cardiac contractility and/or relaxation |
| SG11202111619WA (en) | 2019-05-06 | 2021-11-29 | Cardionomic Inc | Systems and methods for denoising physiological signals during electrical neuromodulation |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
| US5059211A (en) | 1987-06-25 | 1991-10-22 | Duke University | Absorbable vascular stent |
| US5527337A (en) | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
| JP2836878B2 (en) | 1988-08-24 | 1998-12-14 | スリピアン，マービン，ジェイ | Intraluminal sealing with biodegradable polymer material |
| US5085629A (en) | 1988-10-06 | 1992-02-04 | Medical Engineering Corporation | Biodegradable stent |
| US4975280A (en) | 1989-01-23 | 1990-12-04 | Ethyl Corporation | Bioerodable sustained release implants |
| CH678393A5 (en) | 1989-01-26 | 1991-09-13 | Ulrich Prof Dr Med Sigwart | |
| US4994033A (en) | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
| CA2017332A1 (en) * | 1989-06-29 | 1990-12-29 | Richard W. Greiner | Pharmaceutically impregnated catheters |
| JPH077756B2 (en) * | 1989-07-26 | 1995-01-30 | 株式会社日立製作所 | Method for taking samples from supercritical gas equipment |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5258020A (en) | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
| ES2134205T3 (en) | 1991-03-08 | 1999-10-01 | Keiji Igaki | STENT FOR GLASSES, SUPPORT STRUCTURE FOR SAID STENT, AND DEVICE FOR MOUNTING SAID STENT. |
| US5443498A (en) | 1991-10-01 | 1995-08-22 | Cook Incorporated | Vascular stent and method of making and implanting a vacsular stent |
| US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
| WO1993006792A1 (en) | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
| USRE36370E (en) | 1992-01-13 | 1999-11-02 | Li; Shu-Tung | Resorbable vascular wound dressings |
| CA2087132A1 (en) | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
| US5591224A (en) | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Bioelastomeric stent |
| US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
| EP0566245B1 (en) | 1992-03-19 | 1999-10-06 | Medtronic, Inc. | Intraluminal stent |
| US5271400A (en) | 1992-04-01 | 1993-12-21 | General Electric Company | Tracking system to monitor the position and orientation of a device using magnetic resonance detection of a sample contained within the device |
| JP3739411B2 (en) | 1992-09-08 | 2006-01-25 | 敬二 伊垣 | Vascular stent, manufacturing method thereof, and vascular stent device |
| US5449382A (en) | 1992-11-04 | 1995-09-12 | Dayton; Michael P. | Minimally invasive bioactivated endoprosthesis for vessel repair |
| US5443458A (en) | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
| US5340614A (en) | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
| WO1994021196A2 (en) | 1993-03-18 | 1994-09-29 | C.R. Bard, Inc. | Endovascular stents |
| NL9300500A (en) | 1993-03-22 | 1994-10-17 | Industrial Res Bv | Expandable hollow sleeve for locally supporting and / or strengthening a body vessel, as well as a method for manufacturing it. |
| US5456917A (en) | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
| US5441515A (en) | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
| EP0696185B1 (en) | 1993-04-28 | 1998-08-12 | Focal, Inc. | Apparatus, product and use related to intraluminal photothermoforming |
| US5590654A (en) | 1993-06-07 | 1997-01-07 | Prince; Martin R. | Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent |
| US5579767A (en) | 1993-06-07 | 1996-12-03 | Prince; Martin R. | Method for imaging abdominal aorta and aortic aneurysms |
| US5417213A (en) | 1993-06-07 | 1995-05-23 | Prince; Martin R. | Magnetic resonance arteriography with dynamic intravenous contrast agents |
| US5433500A (en) * | 1993-12-17 | 1995-07-18 | New Vision Fiberglass Inc. | Camper shell reinforcement device |
| JP2703510B2 (en) | 1993-12-28 | 1998-01-26 | アドヴァンスド カーディオヴァスキュラー システムズ インコーポレーテッド | Expandable stent and method of manufacturing the same |
| EP0741637B1 (en) * | 1994-01-31 | 1999-07-28 | Bausch & Lomb Incorporated | Treatment of contact lenses with supercritical fluid |
| US5788687A (en) | 1994-02-01 | 1998-08-04 | Caphco, Inc | Compositions and devices for controlled release of active ingredients |
| US5629077A (en) | 1994-06-27 | 1997-05-13 | Advanced Cardiovascular Systems, Inc. | Biodegradable mesh and film stent |
| EP1181904B1 (en) | 1994-10-17 | 2009-06-24 | Kabushikikaisha Igaki Iryo Sekkei | Stent for liberating drug |
| US5549662A (en) | 1994-11-07 | 1996-08-27 | Scimed Life Systems, Inc. | Expandable stent using sliding members |
| US5607518A (en) * | 1995-02-22 | 1997-03-04 | Ciba Geigy Corporation | Methods of deblocking, extracting and cleaning polymeric articles with supercritical fluids |
| US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
| AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
| US5591199A (en) | 1995-06-07 | 1997-01-07 | Porter; Christopher H. | Curable fiber composite stent and delivery system |
| US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
| AU5776696A (en) | 1995-06-08 | 1997-01-09 | Bard Galway Limited | Bifurcated endovascular stent |
| US5744958A (en) | 1995-11-07 | 1998-04-28 | Iti Medical Technologies, Inc. | Instrument having ultra-thin conductive coating and method for magnetic resonance imaging of such instrument |
| US5741293A (en) | 1995-11-28 | 1998-04-21 | Wijay; Bandula | Locking stent |
| US5808060A (en) * | 1995-12-11 | 1998-09-15 | Cephalon, Inc. | Fused isoindolones |
| US5723508A (en) | 1996-01-25 | 1998-03-03 | Northwestern University | Method of fabricating emulsion freeze-dried scaffold bodies and resulting products |
| US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
| US5916585A (en) | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5868781A (en) | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
| WO1998020051A1 (en) * | 1996-11-07 | 1998-05-14 | The Penn State Research Foundation | Short-cycle removal of impurities from polymers |
| US5860467A (en) | 1996-12-03 | 1999-01-19 | The University Of North Carolina At Chapel Hill | Use of CO2 -soluble materials in making molds |
| EP0946222A1 (en) | 1996-12-13 | 1999-10-06 | Data Sciences International, Inc. | Biocompatible medical devices with polyurethane surface |
| US5733330A (en) | 1997-01-13 | 1998-03-31 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent |
| WO1998043695A1 (en) | 1997-03-31 | 1998-10-08 | Kabushikikaisha Igaki Iryo Sekkei | Stent for vessels |
| PT981381E (en) * | 1997-05-12 | 2007-04-30 | Metabolix Inc | Polyhydroxyalkanoates for in vivo applications |
| US6272370B1 (en) | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
| US6267769B1 (en) | 1997-05-15 | 2001-07-31 | Regents Of The Universitiy Of Minnesota | Trajectory guide method and apparatus for use in magnetic resonance and computerized tomographic scanners |
| US6245103B1 (en) | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
| US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
| US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
| US5984957A (en) | 1997-08-12 | 1999-11-16 | Schneider (Usa) Inc | Radially expanded prostheses with axial diameter control |
| WO1999010045A1 (en) | 1997-08-26 | 1999-03-04 | Duke University | Radioactive stent structures |
| US6165196A (en) * | 1997-09-26 | 2000-12-26 | Corvascular Surgical Systems, Inc. | Perfusion-occlusion apparatus |
| US5924987A (en) | 1997-10-06 | 1999-07-20 | Meaney; James F. M. | Method and apparatus for magnetic resonance arteriography using contrast agents |
| US6156062A (en) | 1997-12-03 | 2000-12-05 | Ave Connaught | Helically wrapped interlocking stent |
| US5957975A (en) | 1997-12-15 | 1999-09-28 | The Cleveland Clinic Foundation | Stent having a programmed pattern of in vivo degradation |
| US6001418A (en) | 1997-12-16 | 1999-12-14 | The University Of North Carolina At Chapel Hill | Spin coating method and apparatus for liquid carbon dioxide systems |
| US6179867B1 (en) | 1998-01-16 | 2001-01-30 | Advanced Cardiovascular Systems, Inc. | Flexible stent and method of use |
| US6224626B1 (en) | 1998-02-17 | 2001-05-01 | Md3, Inc. | Ultra-thin expandable stent |
| JP3444781B2 (en) * | 1998-03-10 | 2003-09-08 | 旭化成アイミー株式会社 | Method for modifying medical polymer and medical polymer substrate |
| JPH11335343A (en) * | 1998-05-26 | 1999-12-07 | Nippon Polyurethane Ind Co Ltd | Production of polyfunctional aromatic polyisocyanate |
| US6139511A (en) | 1998-06-29 | 2000-10-31 | Advanced Cardiovascular Systems, Inc. | Guidewire with variable coil configuration |
| CA2340652C (en) | 1998-08-20 | 2013-09-24 | Cook Incorporated | Coated implantable medical device comprising paclitaxel |
| US6120847A (en) | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
| US6312457B1 (en) | 1999-04-01 | 2001-11-06 | Boston Scientific Corporation | Intraluminal lining |
| US6368346B1 (en) * | 1999-06-03 | 2002-04-09 | American Medical Systems, Inc. | Bioresorbable stent |
| US6440405B1 (en) | 1999-06-07 | 2002-08-27 | University Of Delaware | Quaternary ammonium functionalized dendrimers and methods of use therefor |
| CA2379416A1 (en) | 1999-07-09 | 2001-01-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl protease inhibitors and diagnostic imaging agents |
| US6302907B1 (en) | 1999-10-05 | 2001-10-16 | Scimed Life Systems, Inc. | Flexible endoluminal stent and process of manufacture |
| US7226475B2 (en) * | 1999-11-09 | 2007-06-05 | Boston Scientific Scimed, Inc. | Stent with variable properties |
| US6264671B1 (en) | 1999-11-15 | 2001-07-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery catheter and method of use |
| US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
| US6481262B2 (en) * | 1999-12-30 | 2002-11-19 | Advanced Cardiovascular Systems, Inc. | Stent crimping tool |
| US6264683B1 (en) | 2000-03-17 | 2001-07-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery catheter with bumpers for improved retention of balloon expandable stents |
| WO2001070294A2 (en) * | 2000-03-20 | 2001-09-27 | Scimed Life Systems, Inc. | Selective radiopaque plating of a stent |
| US6436132B1 (en) | 2000-03-30 | 2002-08-20 | Advanced Cardiovascular Systems, Inc. | Composite intraluminal prostheses |
| DK1301221T3 (en) * | 2000-05-16 | 2006-07-03 | Ortho Mcneil Pharm Inc | Method of coating medical articles using supercritical carbon dioxide |
| WO2002007785A2 (en) * | 2000-07-20 | 2002-01-31 | Sulzer Carbomedics Inc. | Implantable biocompatible animal tissue |
| JP2002035135A (en) * | 2000-07-31 | 2002-02-05 | Manii Kk | Stent and method for manufacturing stent |
| US6451373B1 (en) | 2000-08-04 | 2002-09-17 | Advanced Cardiovascular Systems, Inc. | Method of forming a therapeutic coating onto a surface of an implantable prosthesis |
| JP4386564B2 (en) * | 2000-11-30 | 2009-12-16 | 日東電工株式会社 | Method of removing low molecular weight material from polyimide precursor or polyimide containing low molecular weight material |
| US20020077691A1 (en) * | 2000-12-18 | 2002-06-20 | Advanced Cardiovascular Systems, Inc. | Ostial stent and method for deploying same |
| US20030044514A1 (en) * | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
| US6945994B2 (en) * | 2001-12-05 | 2005-09-20 | Boston Scientific Scimed, Inc. | Combined balloon-expanding and self-expanding stent |
-
2003
- 2003-09-15 US US10/662,621 patent/US7285287B2/en not_active Expired - Fee Related
- 2003-10-23 AU AU2003284338A patent/AU2003284338B2/en not_active Ceased
- 2003-10-23 WO PCT/US2003/033644 patent/WO2004047873A2/en active Application Filing
- 2003-10-23 CA CA2498180A patent/CA2498180C/en not_active Expired - Fee Related
- 2003-10-23 JP JP2005510351A patent/JP4617258B2/en not_active Expired - Fee Related
- 2003-10-23 EP EP03776520A patent/EP1560489A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006506214A (en) | 2006-02-23 |
| US20040098120A1 (en) | 2004-05-20 |
| WO2004047873A3 (en) | 2004-11-18 |
| WO2004047873A2 (en) | 2004-06-10 |
| AU2003284338B2 (en) | 2009-04-09 |
| CA2498180A1 (en) | 2004-06-10 |
| AU2003284338A1 (en) | 2004-06-18 |
| US7285287B2 (en) | 2007-10-23 |
| JP4617258B2 (en) | 2011-01-19 |
| EP1560489A2 (en) | 2005-08-10 |
| EP1560489A4 (en) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2498180C (en) | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses | |
| AU2004220631B2 (en) | Intraluminal prostheses with annealed polymer coating | |
| AU2003286631B2 (en) | Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents | |
| US7005137B1 (en) | Coating for implantable medical devices | |
| EP1684821B1 (en) | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same | |
| EP1684818B1 (en) | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same | |
| EP1689462B1 (en) | Coatings for implantable devices comprising block copolymers of lactic acid and ethylene glycol | |
| JP2009525809A (en) | Implantable medical device with drug delivery coating with surface erodible polyester | |
| WO2007121041A2 (en) | Inhibition of calcification on an endovascular device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151023 |